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Multidrug-resistant (MDR) pulmonary tuberculosis (TB) is well described in the literature. Reports of MDR
TB meningitis (MDR-TBM), however, are limited to case reports and a single case series. During the period
of 1999–2002, 350 patients with TBM were identified by cerebrospinal fluid culture for TB. Thirty patients
(8.6%) had TB that was resistant to at least isoniazid and rifampicin. All 30 patients were included in this
study. We reviewed hospital charts of the patients with MDR-TBM and describe our experience. Seventeen
patients with MDR-TBM died, and, of those who were known to be alive, many experienced significant
morbidity. Eighteen patients were HIV positive. Twenty-two patients had been treated for TB in the past, 3
patients had received no previous treatment for TB, and the history of TB treatment was unknown for 5
patients. The study highlights the prevalence of MDR-TBM and identifies new challenges in the management
of affected patients.
Tuberculosis (TB) has reemerged as a global epidemic.
Recent data from the World Health Organization
(WHO) suggest that the global incidence is increasing
by 0.4% per annum [1]. In South Africa, the number
of notifications increased from 55,310 cases per annum
in 1980 to 148,257 cases per annum in 2001. The prev-
alence increased from 190 cases per 100,000 people in
1980 to 339 cases per 100,000 people in 2001 [2]. This
has been complicated by the emergence of multidrug-
resistant pulmonary TB. In South Africa, the mean
prevalence of multidrug-resistant pulmonary TB is
1.6% (range, 0.3%–3.3%) among treatment-naive pa-
tients and 6.7% (range, 1.7%–18.8%) among patients
who have previously been treated for TB [3]. In the
province of KwaZulu-Natal, the prevalence of multi-
drug-resistant pulmonary TB among treatment-naive
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patients is 1%–2%, and it is 7%–8% among those who
have previously been treated for TB [3].
The HIV epidemic contributes to the increasing TB
disease burden and to consequent morbidity and mor-
tality. CNS TB accounts for 5% of all cases of extra-
pulmonary TB, and meningitis is the most frequent
complication [4]. Against this background, we antici-
pate an increase in multidrug-resistant TB meningitis.
To date, single case reports and a single case series about
multidrug-resistant TB meningitis have been reported
[5]. We report our experience with a cohort of 30 pa-
tients with multidrug-resistant TB meningitis in
KwaZulu-Natal and discuss the case histories of 2 health
workers in detail.
METHODS
In the public hospitals in KwaZulu-Natal, CSF cultures
are performed at a central laboratory. Samples collected
from 1999 through 2002 that yielded multidrug-resis-
tant TB were included in the study. The biochemical
and cellular changes in the CSF and the resistance pat-
terns noted for these cultures were recorded. After con-
sent was obtained from the relevant hospital managers,
demographic and clinical data were acquired from the
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1 27 F + Yes 2 No No Died
2 18 F + Yes 1 No No Improved
3 32 F + Yes 1 Yes No Improved
4 28 F + Yes 1 Yes No Died
5 11 F + Yes 1 No No Died
6 18 F + Yes 2 Yes Yes Died
7 18 F  Yes 2 Yes Yes Improved
8 37 M + Yes 2 Yes No Died
9 31 F + Yes 2 Yes No Died
10 27 F NA Yes 2 Yes No Improved
11 45 F NA Yes 1 No No Improved
12 30 M + Yes 1 Yes No Died
13 36 M NA Yes 3 Yes No Died
14 20 F + Yes 3 Yes Yes Improved
15 24 F + Yes 1 Yes Yes Improveda
16 29 F NA NA NA NA NA NA
17 26 F  No 3 Yes Yes Improved
18 29 M NA Yes 3 No No Died
19 0.4 F NA NA NA Yes Yes Died
20 8 M + No 2 Yes Yes Improveda
21 21 F + Yes 3 No No Died
22 20 F + Yes 1 Yes No Died
23 32 M + Yes 1 No No Died
24 24 F NA Yes 3 No No Died
25 34 F + Yes 1 No No Died
26 28 F + No 2 No No Died
27 31 M + NA 1 Yes No Died
28 29 M NA Yes 1 No No Improved
29 NA NA NA NA NA NA NA NA
30 NA NA NA NA NA NA NA NA
NOTE. BMRC, British Medical Research Council; NA, not available; +, positive, , negative.
a Receiving antiretroviral therapy.
hospital charts for the patients from whom these samples were
obtained.
Multidrug-resistant TB was defined as Mycobacterium tu-
berculosis that was resistant to at least isoniazid and rifampicin.
All of the patients we describe had TB that was resistant to at
least these 2 drugs.
The British Medical Research Council (BMRC) system for
grading meningitis was used to describe the neurological status
of patients, as follows: grade 1, patient was fully conscious and
rational, and there were no neurological signs; grade 2, patients
was confused but not comatose or had neurological signs, such
as hemiparesis or single cranial nerve palsy; and grade 3, patient
was comatose or stuporose or had multiple cranial nerve palsies
or complete hemiplegia or paraplegia.
RESULTS
Clinical data are summarized in table 1. During the study pe-
riod, a total of 6762 CSF samples obtained for culture for
Mycobacterium tuberculosis. There were 350 cultures positive
for M. tuberculosis (5.2%), 40 (11.4%) of which yielded mul-
tidrug-resistant M. tuberculosis. After excluding additional cul-
ture specimens obtained single patients, the sample size was
reduced to 30 patients (8.6%).
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Inh Rif Emb Sm Eth Kan Ofl Th Cy
1 70 570 7.9 1.4 114  R R R S S S S S S
2 0 88 0.7 1.1 127 + R R S S S S S S S
3 10 58 0.7 2.2 115  R R S S S S S S S
4 14 36 2.7 1.9 105  R R S R R S NA S S
5 NA NA NA NA NA NA R R S R R S S S S
6 68 210 ND ND 101  R R R R R S S S R
7 92 106 0.8 1.6 100  R R R R S S S S S
8 0 4 0.6 0.0 126  R R R R R R S S S
9 0 0 0.7 2.1 (6.3) 118  R R R R R S S R R
10 80 120 2.6 1.3 119  R R R S R S S S S
11 2 118 2.5 1.2 (5.9) 115  R R R R R S S S S
12 28 42 5.4 0.7 (4.3) 115  R R S R S S S S S
13 190 200 2.4 2.6 (10.1 113  R R S R S S S S S
14 114 305 1.7 1.0 114  R R R R R S S S S
15 32 40 1.4 1.8 119  R R S R R S S S S
16 NA NA NA NA NA NA R R S R S S S S S
17 4 2 1.6 1.9 (4.9) 117  Rb Rb Rb Sb NAb NAb NAb NAb NAb
18 10 76 0.3 1.1 95  R R S R S S S S S
19 22 126 2.7 0.7 103  R R S S S S S S S
20 10 10 1.3 1.7 124  R R S S S S S S S
21 56 16 0.7 2.3 100  R R R R S S NA S S
22 60 610 7.8 1.2 (4.2) 114  R R S R S S NA S S
23 30 385 18.0 1.8 104  R R S R R S NA S R
24 NA NA NA NA NA NA R R S S R S S S S
25 860 350 6.5 0.9 105  R R R R R S S S S
26 0 0 0.5 2.4 124 + R R S S S S S S S
27 630 30 1.6 0.5 116  R R S R S S S S S
28 230 120 17.3 2.1 109  R R S R R S S S S
29 NA NA NA NA NA NA R R R R R R S R S
30 NA NA NA NA NA NA R R S S R S NA S S
NOTE. Cy, cycloserine; Emb, ethambutol; Eth, ethionamide; Inh, isoniazid; Kan, kanamycin; NA, not available; ND, not done; Ofl, ofloxacin; PML, polymor-
phonuclear leukocyte; R, resistant; Rif, rifampin; S, susceptible; Sm, streptomycin; Th, thiacetazone; +, positive; , negative.
a CSF glucose.
b Isolate was recovered from a sphenoidal biopsy specimen; CSF culture results were negative.
The mean age was 25.7 years (median age, 28 years; range,
0.4–45 years). There were 21 female patients (70%) and 9 male
patients (30%). Two patients had cryptococcal meningitis in
addition to multidrug-resistant TB meningitis. Twenty-two pa-
tients (73%) had a history of prior exposure to anti-TB therapy,
3 patients (10%) had not previously received treatment for TB,
and this information was not known for 5 patients (17%).
Only 2 patients were known to be HIV negative (table 1),
and these were health care workers who probably acquired
multidrug-resistant TB ab initio. Their conditions improved
while receiving treatment, but they were left with significant
functional impairment. These patients are described in Case
Reports.
The BMRC clinical assessment rating for meningitis was
grade 1 for 8 patients (26.7%), grade 2 for 11 patients (36.7%),
and grade 3 for 8 patients (26.7%). The clinical grade was
unknown in 3 patients (10%). Eighteen patients were HIV
positive (13 of these patients died and 5 were alive), and the
HIV infection status was unknown for 10 patients (4 of these
patients died, 3 were alive, and 3 had unknown outcomes).
Fourteen patients also had pulmonary TB; 2 of these patients
had a miliary pattern (1 with dissemination), and 4 patients
had proven multidrug-resistant pulmonary TB. One patient
had an exudative pleural effusion. In 9 patients, there was no
evidence of TB in any other organ, and, for 6 patients, it was
not known whether there was other organ involvement.
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Table 3. Drug resistance among















The CSF findings and culture susceptibility data are sum-
marized in table 2. In patients 9 and 26, there were no cells
detected in the CSF specimen (one patient had pleural effusion,
and the other had parenchymal lung disease). Both patients
died within a few days after hospital admission. For 2 patients
(patients 8 and 17), !6 cells were noted in the CSF specimen;
both patients also had pulmonary TB. One patient died, and
the other has responded to appropriate drug therapy (see pa-
tient 17 in Case Reports).
Resistance was noted for the agents ethambutol (12 patients),
streptomycin (20 patients), ethionamide (15 patients), kana-
mycin (2 patients), thiacetazone (2 patients), and cycloserine
(2 patients). Tests for pyrazinamide susceptibility are not avail-
able in KwaZulu-Natal; therefore, the susceptibility of M. tu-
berculosis to this drug is not known. The occurrence of my-
cobacterial isolates that were resistant to many more drugs than
just isoniazid and rifampicin (table 3) is of additional concern.
Nine patients were infected with M. tuberculosis that was re-
sistant to rifampicin, isoniazid, ethambutol, and streptomycin.
Seven patients were infected with strains that were resistant to
rifampicin, isoniazid, ethambutol, streptomycin, and ethion-
amide. Five patients were infected with strains that were resis-
tant to only rifampicin and isoniazid.
Only 7 patients were treated with drugs to which the or-
ganism was susceptible. Sixteen patients were treated with pred-
nisone, and, for 3 patients, treatment information was not
known. Of the 7 patients who received both appropriate TB
treatment and prednisone, 2 died. Of the remaining 5 patients
whose conditions improved, 2 also received antiretroviral drugs.
CASE REPORTS
Patient 7. A 19-year-old student health care worker pre-
sented with cough, chest pain, general malaise, and fever. On
the basis of findings from a chest radiograph and sputum smear
results (culture results were negative), pulmonary TB was di-
agnosed, and the student was treated for 6 months with first-
line anti-TB therapy (i.e., rifampicin, isoniazid, pyrazinamide,
and ethambutol). Nine months later, she presented again with
TB lymphadenopathy, which was confirmed histologically. On
this occasion, a second chest radiograph revealed that the pre-
viously treated pneumonia had not resolved. The patient re-
started standard first-line anti-TB therapy and developed drug-
induced hepatitis, for which she was referred to the regional
TB hospital for inpatient management.
Clinical evaluation confirmed asthenia, jaundice, and lymph-
adenopathy, and the findings of a neurological examination
were normal. The patient’s chest radiograph showed lobar
pneumonia. While receiving treatment, she developed a seizure,
and she was investigated for meningitis. Her clinical grade, CSF
changes, and outcome are summarized in tables 1 and 2. The
findings of the initial computerized axial tomography scan of
the brain were unremarkable. Despite receiving treatment, she
became obtunded and developed hyponatremia and hydro-
cephalus. The hydrocephalus was corrected with a ventricu-
loperitoneal shunt, and the patients mental state improved.
Isoniazid- and rifampicin-resistant TB bacilli were isolated
from CSF specimens. A second-line treatment regimen that
included ethionamide, cycloserine, ciprofloxacin, and ami-
kacin was added to therapy. Her clinical course was compli-
cated by a pontine infarct. The patient is currently quadris-
pastic, and although she is alert, she remains “locked in” (i.e.,
the patient is fully awake but unable to move or communi-
cate). The most recent CSF and sputum culture results were
negative.
Patient 17. A 26-year-old health care worker presented to
her physician with a 3-week history of fever, weakness, and
malaise. She completed a course of antibiotics, but her con-
dition did not improve. A chest radiograph showed left upper
lobe infiltration and left hilar lymphadenopathy. A presumptive
diagnosis of pulmonary TB was made, and treatment with first-
line anti-TB drugs and pyridoxine was commenced. The patient
then complained of headache and vomiting. Four weeks after
onset of symptoms, she had a generalized seizure. She became
jaundiced and also had neck stiffness. The findings of an initial
CT scan of the brain with contrast were normal. The CSF
findings were consistent with TB meningitis (tables 1 and 2).
MRI of the brain was performed 2 months later and showed
basal enhancement and sphenoidal sinusitis. The neck stiffness
worsened, and the patient developed bilateral abducens nerve
palsies and a right facial nerve palsy. A brain CT performed at
this time revealed hydrocephalus. A ventriculoperitoneal shunt
was inserted.
During the interval between the initial CT and the MRI,
multidrug-resistant M. tuberculosis was cultured from a sputum
sample and also from fluid from the sphenoid sinus. The treat-
ment regimen was changed to pyrazinamide, ofloxacin, cyclo-
serine, ethionamide, amikacin, pyridoxine, and prednisone.
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When assessed 6 months after the onset of illness, the pa-
tient’s condition had stabilized, but the patient had grade 4/5
weakness of both arms and legs, right facial weakness, and
resolving sixth nerve palsies. An additional MRI, which in-
cluded the cervical spine, still showed extensive meningeal en-
hancement, and ischemic lesions in the pons and left basal
nuclei were noted.
DISCUSSION
Treatment for TB meningitis is usually initiated when there is
clinical suspicion, because any delay in treatment results in
significant morbidity, and failure to treat is associated with a
high case-fatality rate. The low sensitivity of CSF smears and
culture and the prolonged time required for culturing and sus-
ceptibility testing make TB meningitis a difficult diagnosis to
confirm. Thus, the findings underestimate the true incidence
of multidrug-resistant TB meningitis. The emergence of mul-
tidrug-resistant TB meningitis complicates the management of
TB meningitis, because the first-line anti-TB regimen is inad-
equate, and there is an additional delay before the susceptibility
pattern is known. The total duration of the delay could be up
to 10 weeks, leading to even greater morbidity and mortality.
There is an urgent need for more sensitive and rapid diagnostic
techniques that can be implemented in resource-poor settings,
but these are unlikely to be forthcoming in the next few years.
Our study supports the findings in the literature that patients
with multidrug-resistant TB are likely to have a history of pre-
vious treatment for TB. It is disconcerting that 2 patients in
this cohort had TB that was resistant to 7 drugs. The impli-
cation of this high level of resistance is that there were only 3
drugs available to treat these patients. If translated into epi-
demic proportions, such cases would be extremely difficult to
manage, and there would be devastating consequences. These
“pan-resistant” organisms have also been isolated in Peru [6].
The published data on multidrug-resistant TB meningitis is
confined to single case reports and a short case series [7–10].
These reports also highlight the morbidity and mortality as-
sociated with multidrug-resistant TB meningitis. Our cohort
comprises young individuals, most (70%) of whom were fe-
male. Seventeen patients died, and those who survived were
left with significant functional impairment. There was no de-
finitive association between clinical grade, administration of
prednisone, and outcome, although we acknowledge that the
sample size was small. However, most of the culture and sus-
ceptibility test results were received after the patients had died
or had been discharged from the hospital; as a consequence,
only a few patients received appropriate treatment, which may
account for the poor outcomes. Contributing factors associated
with mortality were comorbid disease related to other organ
involvement (such as liver dysfunction, bone marrow phthisis,
and respiratory dysfunction) and receipt of inappropriate treat-
ment for TB (CSF susceptibility results became available post-
humously). Of the patients for whom a history of previous
treatment for TB was known, only 2 patients (a health care
worker and a child) were not treated for TB previously.
Established factors that contribute to TB drug resistance are
1 of the following variables: an erratic drug supply, prescrip-
tion of inadequate chemotherapy, poor patient management,
and nonadherence to therapy and treatment interruptions [11].
In South Africa, despite the implementation of the WHO’s
directly observed therapy short-course (DOTS) strategy, cure
rates for drug-susceptible pulmonary TB improved from 34%
to only 54% [2]. This translates into higher rates of multidrug-
resistant pulmonary and consequent extrapulmonary TB. The
HIV epidemic further fuels the TB epidemic [12–16], and un-
less interventions are introduced to improve cure rates for drug-
susceptible TB, the prevalence of multidrug-resistant TB will
be aggravated.
Poorly managed TB-control programs, together with the HIV
epidemic, will result in more cases of multidrug-resistant TB
and, consequently, a larger number of cases of multidrug-
resistant TB meningitis, with considerable morbidity and mor-
tality. This poses a greater management challenge for the phy-
sician. From a public health point of view, a more aggressive
case finding and treatment campaign is needed to control the
pool of multidrug-resistant TB, which has caused institutional
outbreaks with high rates of transmission in the United States,
Europe, and Latin America.
In countries where multidrug-resistant TB is a growing prob-
lem and HIV infection has already reached epidemic propor-
tions, adopting the DOTS strategy alone is insufficient to con-
trol the spread of TB [17]. In settings such as these, where
health care workers are exposed to patients with undiagnosed
and/or inappropriately treated multidrug-resistant TB, rigorous
infection-control measures must be implemented to reduce the
risk of nosocomial transmission. In the local TB hospital, the
HIV seroprevalence among patients with multidrug-resistant
pulmonary TB who consented to HIV testing is 22% (N. Pa-
dayatchi, personal communication). In this study, 18 patients
(60%) were HIV seropositive, 2 (7%) were HIV seronegative,
and the HIV infection status was unknown for 10 patients
(33%). Among the patients with a known outcome, the mor-
tality rate was 56%. Seventy-six percent of the patients who
died had HIV infection. The subsequent outcome for patients
who were documented as having “improved” is also unknown,
and they may well have had a similar fate.
Management of multidrug-resistant TB in South Africa is
100 times more expensive than is management of drug-
susceptible TB, and second-line anti-TB drugs are not as ef-
fective as first-line drugs: with the exception of ethionamide,
the CSF penetration is poor. There is also a paucity of phar-
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macokinetic data for drugs such as cycloserine and thiacetazone
[18–20]. Similarly, there are insufficient data regarding the ef-
fectiveness of the second-line drugs against intracellular or-
ganisms. With the exception of the fluoroquinolones, the other
drugs are bacteriostatic. The CSF concentration of ciprofloxacin
has only reached 16%–20% of the serum levels in phase 1 trials
[21], and these levels may not be adequate for efficacy against
slow-growing organisms like M. tuberculosis. Because there have
not been any controlled studies, the optimal combination of
drugs and the duration of therapy are empirical. Although stud-
ies have shown that the response to standard anti-TB therapy
is similar in patients with drug-susceptible TB meningitis, re-
gardless of HIV infection status [5, 22–25], the response in
patients with multidrug-resistant TB meningitis is unknown.
Anecdotal reports indicate that the response is poor.
Clinical trials are required to systematically study the second-
line drugs so that national protocols can be developed. In the
interim, the guidelines of the British Thoracic Society [26] may
be adopted. A history of prior exposure to anti-TB drugs in a
patient with signs and symptoms of meningitis should alert the
clinician to the possibility of multidrug-resistant TB meningitis,
and an aggressive approach to investigating such patients is
advocated.
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